High Risk, High Impact: Rare Disease Biotech Reclaims Investor Attention

Mirum’s agreement to buy Bluejay highlights renewed investor interest and growing competition for late-stage rare disease assets

9 Dec 2025

Rare disease biotech is picking up speed, and Mirum Pharmaceuticals’ move to acquire Bluejay Therapeutics has become a clear turning point. Valued at up to 820 million dollars, the deal highlights how quickly attention is shifting toward conditions long overlooked by the drug industry.

For years, rare diseases sat on the margins of biotech strategy. Today, they are increasingly seen as a source of both scientific breakthroughs and durable growth. Mirum’s bid reflects that change. Investors and drugmakers are now racing to secure assets that could redefine care for small but deeply underserved patient groups.

At the center of the transaction is brelovitug, a late stage Phase 3 therapy for chronic hepatitis D. The disease is ultra rare, life threatening, and has no approved treatments in the United States. For many observers, the appeal of the deal goes beyond pipeline expansion. It signals a serious attempt to close a long standing gap in liver disease care.

Mirum’s leadership has framed the acquisition as a patient driven move, with an emphasis on advancing brelovitug as quickly and carefully as possible. That message resonates in a space where patients often wait years for meaningful progress.

The structure of the deal also tells a larger story. Mirum is paying a mix of cash and stock, with a sizable portion tied to future performance. The company has also raised fresh capital from healthcare focused investors. Together, those moves point to growing confidence that rare disease programs can deliver both medical impact and predictable returns.

Competition is adding fuel. Larger drugmakers, including Novo Nordisk, have pushed further into rare diseases, a field once dominated by smaller specialists. Clearer regulatory paths and steady demand from specialty clinics have made the space more attractive.

Challenges remain. Small patient populations complicate trials, and orphan drug pricing continues to draw scrutiny. Still, momentum is hard to ignore.

If brelovitug clears its final hurdles, Mirum’s gamble could reshape the competitive landscape and offer new hope to patients who have had few options. In rare disease biotech, the race is clearly on.